A study indicates psilocybin shows promise for treating depression, aligning with ongoing research into novel psychotropic treatments for mood disorders.
Preclinical or early clinical evidence suggests psilocybin may be effective for treating cocaine use disorder, highlighting the expanding scope of psychedelic research beyond approved psychiatric indications.
This literature review evaluates the potential of GLP-1 receptor agonists to mitigate metabolic side effects associated with clozapine or olanzapine therapy.
A small clinical trial indicates that a single dose of psilocybin provides rapid relief from depression, highlighting its potential as a fast-acting psychotropic intervention.
This meta-analysis evaluates the efficacy of mood stabilizers for adolescent nonsuicidal self-injury, highlighting lithium's potential benefit and challenging the consistent therapeutic effects of antidepressants in this population.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from May 14 – May 18)
- Monitor for severe sedation and coma risk when titrating clozapine, particularly in patients with a history of intoxication or rapid dose escalation.
- Counsel patients at clinical high risk for psychosis that concurrent cannabis and tobacco use triples their risk of developing a psychotic disorder.
- Consider lithium as a first-line mood stabilizer for adolescent nonsuicidal self-injury, given its demonstrated benefit where antidepressants show inconsistent efficacy.
- Reassure patients regarding antidepressant use during pregnancy, as large-scale data indicates no clear link to autism or ADHD in offspring.
- Evaluate GLP-1 receptor agonists as a potential strategy to mitigate metabolic side effects in patients requiring long-term clozapine or olanzapine therapy.
- Recognize that psilocybin is emerging as a fast-acting intervention for depressive disorders, with evidence supporting rapid relief after a single dose.
- Consider the emerging evidence for GLP-1 receptor agonists in the pharmacological treatment of Alcohol Use Disorder when managing comorbid substance use.
- Investigate zervimesine as a potential new treatment option for neuropsychiatric symptoms, such as psychosis and hallucinations, in dementia with Lewy bodies.
- Be aware that preclinical and early clinical evidence suggests psilocybin may be effective for treating cocaine use disorder, expanding its therapeutic scope beyond mood disorders.
- Utilize the provided clinical guidance on teratogenic risks versus relapse prevention to balance decision-making when prescribing psychotropics during pregnancy and lactation.
Drug Development 3
A phase 1 open-label trial is recruiting to evaluate the safety and feasibility of the NST-SPARK device for the treatment of schizophrenia and schizoaffective disorder.
Phase 2 trial of XPro1595, a selective soluble TNF inhibitor, failed to meet its primary endpoint in early Alzheimer disease overall but showed directional cognitive and biomarker benefits in a prespecified inflammation-enriched subgroup, supporting a phase 3 strategy focused on inflammatory phenotypes.
Investigational drug zervimesine for dementia with Lewy bodies showed reductions in neuropsychiatric symptoms like psychosis and hallucinations in clinical trials, representing a potential new treatment option for a core psychiatric manifestation of neurodegenerative disease.
Substance Use 2
Co-use of cannabis and tobacco triples the risk of developing psychotic disorders in individuals at clinical high risk, highlighting a critical substance use interaction for psychiatrists managing psychosis prevention.
Clinical Pearl 1
Case report of 70-hour coma due to clozapine intoxication, highlighting the risk of severe sedation and the need for careful dose titration and monitoring.
Diagnosis & Treatment 5
A clinical trial is recruiting participants with Major Depressive Disorder to evaluate the Motif XCS System, a neuromodulation device developed by Motif Neurotech.
This article provides clinical guidance on decision-making and risk assessment for prescribing psychotropic medications during pregnancy and lactation.
This article discusses the clinical challenge of balancing teratogenic risks against the risk of psychiatric relapse when prescribing psychotropic medications during pregnancy.
This article examines trends in psychotropic medication prescribing patterns across various medical providers from 2016 to 2019, offering insights into the distribution of psychiatric pharmacotherapy in general practice.
A new study from Karolinska Institutet indicates that a single dose of psilocybin provides rapid relief from depression, highlighting its potential as a fast-acting treatment for depressive disorders.
Digital Health 1
A clinical trial is recruiting to evaluate the efficacy of EEG neurofeedback for improving working memory in patients with schizophrenia and schizoaffective disorder.